BofA analyst Jason Zemansky raised the firm’s price target on BridgeBio (BBIO) to $50 from $46 and keeps a Buy rating on the shares. Despite concerns over Attruby’s early launch, BridgeBio reported “strong” Q1 results, the analyst tells investors. The firm is increasing its Attruby forecasts and sees a “compelling risk/ reward” given what it sees as a still underappreciated pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Cautious Outlook for BridgeBio Pharma Amid Competitive Pressures and Market Uncertainties
- BridgeBio price target raised to $63 from $46 at Piper Sandler
- BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50
- BridgeBio Pharma Reports Q1 2025 Earnings and Pipeline Progress
- BridgeBio reports Q1 EPS (88c), consensus ($1.00)